Compare BioNano Genomics Inc (BNGO) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Royal Caribbean Cruises Ltd — how do they compare? BioNano Genomics Inc trades at $1.24 (market cap $13.66M), while Royal Caribbean Cruises Ltd trades at $307.99 (market cap $82.15B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 6013.9× BioNano Genomics Inc's market cap, and Royal Caribbean Cruises Ltd pays a 1.63% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | RCL | |
|---|---|---|
Market Cap | $13.66M | $82.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $365.84 |
52-Week Low | $1.06 | $246.71 |
Enterprise Value | $16.26M | $104.79B |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Royal Caribbean (RCL) trades at $307.87, showing minimal daily movement (-0.04%) with a bullish technical signal. The company demonstrates strong fundamental momentum with Q2 2026 EPS beating expectations at $4.21 versus $3.98, and robust profitability metrics including 23.54% net income margin and 45.33% ROE. Recent news highlights strong demand trends and the pricing of $1.25 billion in senior notes to support growth initiatives.
RCL presents a compelling growth story with record bookings and improved financial health, though elevated valuation ratios (P/E 18.97, P/S 4.46) and geopolitical risks in Europe warrant caution. Analyst consensus remains positive with a $343.09 price target, suggesting approximately 11% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
